Treatment of Resectable Locoregional VIPoma Located in the Distal Pancreas (Body or Tail)
Clinical Scenario
Resectable locoregional VIPoma — a VIP-secreting pancreatic neuroendocrine tumor — sited in the body or tail of the pancreas. The tumor is amenable to surgical resection, and the clinical picture is dominated by the hormonal consequences of uncontrolled VIP secretion.
Approach Overview
Management combines somatostatin analogue therapy for symptom and tumor control with correction of metabolic disturbances, followed by definitive surgical resection. The operative strategy is guided by tumor size and its exact position within the distal pancreas.
Full agent selection, operative decisions, sequencing, and dosing details are available in the complete protocol.
Treatment Goals
- Resolution of severe watery diarrhea
- Correction of hypokalemia
- Correction of electrolyte imbalance and dehydration
- Symptom and tumor control
References
- Distal VIPomas are treated with distal pancreatectomy with resection of peripancreatic lymph nodes and with or without splenectomy.
- Tumors of the head are generally treated with pancreatoduodenectomy (Whipple procedure); tumors of the body and tail are treated with distal pancreatectomy and splenectomy or spleen-preserving distal pancreatectomy.
- For symptom and/or tumor control, octreotide LAR 20–30 mg IM or lanreotide 120 mg SC every 4 weeks.
- Correct electrolyte imbalance (K+, Mg2+, HCO3-) and dehydration.
View source ↗